Se hai scelto di non accettare i cookie di profilazione e tracciamento, puoi aderire all’abbonamento "Consentless" a un costo molto accessibile, oppure scegliere un altro abbonamento per accedere ad ANSA.it.

Ti invitiamo a leggere le Condizioni Generali di Servizio, la Cookie Policy e l'Informativa Privacy.

Puoi leggere tutti i titoli di ANSA.it
e 10 contenuti ogni 30 giorni
a €16,99/anno

  • Servizio equivalente a quello accessibile prestando il consenso ai cookie di profilazione pubblicitaria e tracciamento
  • Durata annuale (senza rinnovo automatico)
  • Un pop-up ti avvertirà che hai raggiunto i contenuti consentiti in 30 giorni (potrai continuare a vedere tutti i titoli del sito, ma per aprire altri contenuti dovrai attendere il successivo periodo di 30 giorni)
  • Pubblicità presente ma non profilata o gestibile mediante il pannello delle preferenze
  • Iscrizione alle Newsletter tematiche curate dalle redazioni ANSA.


Per accedere senza limiti a tutti i contenuti di ANSA.it

Scegli il piano di abbonamento più adatto alle tue esigenze.

Italians see better pancreatic cancer treatment

Italians see better pancreatic cancer treatment

Verona University-led team publishes findings

Verona, 18 April 2016, 16:31

ANSA Editorial

ANSACheck

- ALL RIGHTS RESERVED

-     ALL RIGHTS RESERVED
- ALL RIGHTS RESERVED

An international group of researchers led by Verona University's Davide Melisi have come up with a new therapeutic strategy for treating patients affected with advanced pancreatic surgery.
    The researchers have shown that a molecule called galunisertib is capable of inhibiting the action of TGFβ, one of the main factors in the disease's growth and spread.
    The new drug, in addition to standard chemotherapy with gemcitabina, can in fact increase in a statistically significant manner, overall survival and survival free of disease progression in patients with advanced pancreatic cancer and a very favourable toxicity profile.
    The results of the clinical trials with galunisertib were presented today that the annual meeting of the American Association for Cancer Research in New Orleans.
    "Cancer of the pancreas," said Melisi, "is one of the deadliest and least explored human tumours.
    "The severe prognosis of our patients is basically linked to phenomena of precocious metastasization during the development of this disease, which are responsible for the already advanced onset of most cases, the intrinsic aggressiveness of this disease, and, above all, the limited efficacy of current treatments with classic chemotherapy drugs.
    "For this reason, in the last few years, we have focused our studies on the role of the various signals induced by TGFβ which are the reason of the particular resistance of the cancer to classic chemotherapy drugs in various preclinical trials".
    The international clinical trials were conducted in Verona by the Clinical Research Centre of the hospital to assess the efficacy and tolerability of the treatment with gemcitabina in combination with the new drug in in 156 patients affected by advanced cancer of the pancreas.
   

ALL RIGHTS RESERVED © Copyright ANSA

Not to be missed

Share

Or use

ANSA Corporate

If it is news,
it is an ANSA.

We have been collecting, publishing and distributing journalistic information since 1945 with offices in Italy and around the world. Learn more about our services.